AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Symvivo Corporation Announces Collaboration with Merck

January 5, 2021 GMT

BURNABY, British Columbia--(BUSINESS WIRE)--Jan 5, 2021--

Symvivo Corporation, a clinical-stage biotechnology company advancing a proprietary bacTRL™ gene delivery platform, announced today that it has entered into a research collaboration with Merck Sharp and Dohme Corp. Under the terms of the agreement, Merck receives an option to take an exclusive license to Symvivo’s bacTRL™ platform technology for use in advancing delivery of oral vaccines.

“We are excited to be collaborating with Merck on this novel program,” said Lloyd Mackenzie, President and Chief Operating Officer at Symvivo. “This agreement builds on Symvivo’s efforts to develop the bacTRL™ platform across a range of diverse and important indications.”

ADVERTISEMENT

About Symvivo

Symvivo is a clinical-stage biotechnology company advancing a proprietary platform for the site-specific delivery of genes for the treatment and prevention of life-threatening diseases. Symvivo’s bacTRL™ platform technology delivers plasmid DNA, both orally and through IV application, that enables a patient’s own cells to produce therapeutic proteins. Symvivo is advancing therapeutics in the area of oral DNA vaccines, oncology, immunology and protein therapy. Symvivo is headquartered in Burnaby, British Columbia. For more information, visit www.symvivo.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210105005131/en/

CONTACT: Canadian Media:

Chantal Allan

Sam Brown Inc. Healthcare Communications

T: 613-319-4384 (CAN)

T: 805-242-3080 (US)

E:chantalallan@sambrown.comUS Media:

Mike Beyer

Sam Brown Inc. Healthcare Communications

T: 312-961-2502

E:mikebeyer@sambrown.com

KEYWORD: NORTH AMERICA CANADA

INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY HEALTH GENETICS CLINICAL TRIALS

SOURCE: Symvivo Corporation

Copyright Business Wire 2021.

PUB: 01/05/2021 09:00 AM/DISC: 01/05/2021 09:01 AM

http://www.businesswire.com/news/home/20210105005131/en